Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBLINGUALGeneric

NOCDURNA

DESMOPRESSIN ACETATE

Standard Dose
0.0277MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview NOCDURNA is listed in Drugs@FDA under application 022517 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient DESMOPRESSIN ACETATE Form and strength TABLET;SUBLINGUAL - 0.0277MG Sponsor FERRING PHARMS INC Submission history Latest submission status date: 2018-06-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview NOCDURNA is listed in Drugs@FDA under application 022517 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DESMOPRESSIN ACETATE Form and strength TABLET;SUBLINGUAL - 0.0277MG Sponsor FERRING PHARMS INC Submission history Latest submission status date: 2018-06-21 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
NOCDURNA (DESMOPRESSIN ACETATE) | Drug Monograph | MedicHelpline